Article
Multidisciplinary Sciences
Suad Hannawi, Linda Saifeldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Shuping Xu, Jian Li, Dongfang Liu, Adam Abdul Hakeem Baidoo, Dima Ibrahim, Mojtaba Alhaj, Yuanxin Chen, Qiang Zhou, Liangzhi Xie
Summary: The safety and immunogenicity of a protein-based tetravalent vaccine SCTV01E were evaluated and compared with a bivalent protein vaccine SCTV01C and a monovalent mRNA vaccine. The results showed that SCTV01E had superior neutralizing antibody levels and immune response compared to the other two vaccines.
NATURE COMMUNICATIONS
(2023)
Article
Biotechnology & Applied Microbiology
Li-Wei Shi, Juan Li, Bang-Wei Yu, Li-Rong Huang, Ke Li, Min Ji, Ling-Yun Zhou, Lin Yuan, Shu-Yuan Yang, Jing-Jing Chen, Ling Wang, Zhi-Wei Jiang, Rong-Cheng Li, Yan-Ping Li, Jie-Lai Xia, Zhao-Jun Mo, Chang-Gui Li
Summary: This study evaluated the safety and immunogenicity of a new bivalent HPV16/18 vaccine, and found that it induced high levels of neutralizing antibodies in females of different age groups, which persisted for up to 48 months in the 9-17-year-old age group.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Ivan T. Lee, Raffael Nachbagauer, David Ensz, Howard Schwartz, Lizbeth Carmona, Kristi Schaefers, Andrei Avanesov, Daniel Stadlbauer, Carole Henry, Ren Chen, Wenmei Huang, Daniela Ramirez Schrempp, Jintanat Ananworanich, Robert Paris
Summary: Despite vaccine availability, influenza remains a significant global public health concern. Preliminary results from a phase 1/2 clinical trial show that mRNA-1010, a quadrivalent mRNA vaccine against seasonal influenza, is safe and elicits a strong immune response in adults. The vaccine produces higher or comparable levels of hemagglutination inhibition (HAI) antibodies compared to the licensed comparator vaccine.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Gwenn Waerlop, Yorick Janssens, Bart Jacobs, Franziska Jarczowski, Andre Diessner, Geert Leroux-Roels, Victor Klimyuk, Isabel Leroux-Roels, Frank Thieme
Summary: The development of an effective norovirus vaccine is crucial for reducing the global burden of norovirus-associated diseases. A clinical trial on 60 healthy adults showed that the norovirus vaccine candidate rNV-2v induced significant humoral and cellular immune responses, and cross-reactive immune response against different norovirus strains was observed.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Mine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, Orhan Yildiz, Ilhami Celik, Hamdi Levent Doganay, Sukran Kose, Sila Akhan, Emin Halis Akalin, Zafer Sezer, Aykut Ozdarendeli, Serhat Unal
Summary: This study presents interim results comparing the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC and CoronaVac. The results show that TURKOVAC is non-inferior to CoronaVac in preventing symptomatic COVID-19 and has a good safety profile.
Article
Biochemistry & Molecular Biology
Fan-Yue Meng, Fan Gao, Si-Yue Jia, Xiang-Hong Wu, Jing-Xin Li, Xi-Ling Guo, Jia-Lu Zhang, Bo-Pei Cui, Zhi-Ming Wu, Ming-Wei Wei, Zhi-Long Ma, Hai-Lin Peng, Hong-Xing Pan, Lin Fan, Jing Zhang, Jiu-Qin Wan, Zhong-Kui Zhu, Xue-Wen Wang, Feng-Cai Zhu
Summary: The vaccine was tested in two trials in China, showing that after three doses, it is safe and induces significant immune responses in healthy individuals aged 18 and older.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Multidisciplinary Sciences
Nastiti Kaswandani, Bernie Endyarni Medise, Elcha Leonard, Hindra Irawan Satari, Julitasari Sundoro, Sri Rezeki Harun Hadinegoro, Ade Putra, Putra Fajar Angkasa
Summary: This study evaluated the incidence rate and severity of Adverse Events Following Immunization (AEFI) of inactivated SARS-CoV-2 vaccine in Indonesia from the first quarter of 2021 to the second quarter of 2022. The results showed that the Sinovac/CoronaVac vaccine used in Indonesia is safe, with most adverse events classified as unrelated to the vaccine or coincidental events.
Article
Pharmacology & Pharmacy
Hanjing Chen, Weili Chen, Fei Yuan, Qingcheng Guo, Xunmin Zhang, Chenguang Wang, Xuening Li
Summary: This study evaluated the bioequivalence of CMAB807, a biosimilar to denosumab, for the treatment of osteoporosis. The results showed that CMAB807 had similar pharmacokinetics, pharmacodynamics, safety, and immunogenicity to denosumab. CMAB807 could potentially be a new treatment option for patients with osteoporosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Jose Luis Arredondo, Sandra Maria Villagomez Martinez, Maria Concepcion Morales, Stephanie Meyer, Myew-Ling Toh, Celine Zocchetti, Claire Vigane, Cesar Mascarenas
Summary: The study evaluated the immunogenicity and safety of co-administered or sequentially administered CYD-TDV and bivalent HPV vaccine in girls aged 9-14 years. The results showed comparable immune responses and safety profiles for both vaccines in dengue seropositive girls aged 9-14 years.
Article
Immunology
Sai Krishna Susarla, Madhu Gupta, Kheya Ghosh Uttam, Sonali Palkar, Ashish Ramachandra Dhongade, K. Siva Ram Prasad, Vasudev Rajapantula, M. D. Ravi, N. Pradeep, M. Satish, B. C. Rajashakar, G. Sandhya, L. Rajendra, Devi Prasad Sahoo, Anand Kumar Kanakasapapathy
Summary: The study shows that Havisure(TM) vaccine is immunogenic and safe for healthy subjects aged 12 months to 49 years, and it is non-inferior to Havrix(R) vaccine.
Article
Pharmacology & Pharmacy
Guoying Cao, Jingjing Wang, Jinjie He, Yingying Hu, Haijing Yang, Linling Que, Xianghong Gu, Jicheng Yu, Xiaojie Wu, Jufang Wu, Wei Fang, Qing He, Jing Zhang
Summary: This study aimed to investigate the pharmacokinetics, safety, and immunogenicity of LZM008 and evaluate its similarity to wtocilizumab in Chinese healthy male subjects. The results showed that LZM008 exhibited similar pharmacokinetic characteristics and safety profiles to the reference product, ACTEMRA (R).
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
E. E. Walsh, G. Perez Marc, A. M. Zareba, A. R. Falsey, Q. Jiang, M. Patton, F. P. Polack, C. Llapur, P. A. Doreski, K. Ilangovan, M. Ramet, Y. Fukushima, N. Hussen, L. J. Bont, J. Cardona, E. DeHaan, G. Castillo Villa, M. Ingilizova, D. Eiras, T. Mikati, R. N. Shah, K. Schneider, D. Cooper, K. Koury, M. -M Lino, A. S. Anderson, K. U. Jansen, K. A. Swanson, A. Gurtman, W. C. Gruber, B. Schmoele-Thoma
Summary: The RSVpreF vaccine showed efficacy in preventing RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (>= 60 years of age), with no evident safety concerns.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Immunology
Tae Hyong Kim, Jung-Hyun Choi, Sun Hee Park, Jin-Hong Yoo, Dong Gun Lee, Su-Mi Choi, Yang Ree Kim, Mi Suk Lee, Eun Ju Choo, Hee Jung Choi
Summary: This study evaluated the immunogenicity and safety of inactivated quadrivalent influenza vaccine in healthy participants aged > 65 years. The vaccine showed seroprotection against four strains of seasonal influenza and no serious adverse events related to the study vaccine were reported. The quadrivalent split influenza vaccine is expected to offer protection against influenza A and both influenza B lineages even in the elderly population.
Article
Biotechnology & Applied Microbiology
Indraneel Basu, Manish Agarwal, Viral Shah, Vijay Shukla, Sunil Naik, Pravin Dinkar Supe, Manoj Kumar Srivastava, Kanakapura Vrushabaiah Giriraja, Peersab Pinjar, Pradeep Kumar Mishra, Shishir Joshi, Ranjit Vijayakumar, Serge van de Witte
Summary: This study compared the immunogenicity and safety profile of two quadrivalent influenza vaccines in different age groups, showing that Influvac (R) Tetra vaccine elicited a good immune response. The seroprotection rates and seroconversion rates were similar for both vaccines, and adverse events were minimal.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Juan Li, Li-Wei Shi, Ke Li, Li-Rong Huang, Jian-Biao Li, Yu-Lian Dong, Wei Li, Min Ji, Qing Yang, Ling-Yun Zhou, Lin Yuan, Xue-Mei Yan, Jing-Jing Chen, Zhi-Wei Jiang, Yang-Yang Qi, Rong-Cheng Li, Yan-Ping Li, Jie-Lai Xia, Bang-Wei Yu, Zhao-Jun Mo, Chang-Gui Li
Summary: This study assessed the immunogenicity and antibody persistence of a novel bivalent HPV vaccine in Chinese females. The results showed that two doses of the vaccine in adolescent girls were non-inferior to three doses in young women. This suggests that the two-dose vaccine has comparable immunogenicity in adolescent girls.
Article
Immunology
David I. Bernstein, Anna Wald, Terri Warren, Kenneth Fife, Stephen Tyring, Patricia Lee, Nick Van Wagoner, Amalia Magaret, Jessica B. Flechtner, Sybil Tasker, Jason Chan, Amy Morris, Seth Hetherington
JOURNAL OF INFECTIOUS DISEASES
(2017)
Article
Virology
Bryan T. Mayer, Elizabeth M. Krantz, David Swan, James Ferrenberg, Karen Simmons, Stacy Selke, Meei-Li Huang, Corey Casper, Lawrence Corey, Anna Wald, Joshua T. Schiffer, Soren Gantt
JOURNAL OF VIROLOGY
(2017)
Article
Immunology
C. M. Posavad, L. Zhao, L. Dong, L. Jin, C. E. Stevens, A. S. Magaret, C. Johnston, A. Wald, J. Zhu, L. Corey, D. M. Koelle
MUCOSAL IMMUNOLOGY
(2017)
Article
Immunology
Laura P. Newman, Anne Njoroge, Amalia Magaret, Bhavna H. Chohan, Veronicah W. Gitomea, Anna Wald, Jonathan Gorstein, Julie Overbaugh, Dalton Wamalwa, Elizabeth Maleche-Obimbo, Ruth Nduati, Carey Farquhar
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2017)
Article
Multidisciplinary Sciences
David M. Koelle, Peter Norberg, Matthew P. Fitzgibbon, Ronnie M. Russell, Alex L. Greninger, Meei-Li Huang, Larry Stensland, Lichen Jing, Amalia S. Magaret, Kurt Diem, Stacy Selke, Hong Xie, Connie Celum, Jairam R. Lingappa, Keith R. Jerome, Anna Wald, Christine Johnston
SCIENTIFIC REPORTS
(2017)
Letter
Microbiology
Amalia S. Magaret, Anna Wald
Article
Ophthalmology
Cecilia S. Lee, Aaron Y. Lee, Lakshmi Akileswaran, David Stroman, Kathryn Najafi-Tagol, Steve Kleiboeker, James Chodosh, Amalia Magaret, Anna Wald, Russell N. Van Gelder
Article
Immunology
Joshua T. Schiffer, Dave A. Swan, Pavitra Roychoudhury, Jennifer M. Lund, Martin Prlic, Jia Zhu, Anna Wald, Lawrence Corey
JOURNAL OF IMMUNOLOGY
(2018)
Editorial Material
Medicine, General & Internal
Amalia S. Magaret, Shevin T. Jacob, M. Elizabeth Halloran, Katherine A. Guthrie, Craig A. Magaret, Christine Johnston, Noah R. Simon, Anna Wald
ANNALS OF INTERNAL MEDICINE
(2020)
Editorial Material
Medicine, General & Internal
Ruanne V. Barnabas, Anna Wald
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Microbiology
Alexandra M. Johansson, Uma Malhotra, Yeseul G. Kim, Rebecca Gomez, Maxwell P. Krist, Anna Wald, David M. Koelle, William W. Kwok
Summary: This study identified SARS-CoV-2 CD4+ T cell epitopes using tetramer reagents, distinguishing immunodominant and subdominant epitopes. Among the four potential Spike-specific cross-reactive epitopes identified, three were subdominant epitopes, while only one was an immunodominant epitope.
Article
Medicine, Research & Experimental
Rebecca Elyanow, Thomas M. Snyder, Sudeb C. Dalai, Rachel M. Gittelman, Jim Boonyaratanakornkit, Anna Wald, Stacy Selke, Mark H. Wener, Chihiro Morishima, Alexander L. Greninger, Michael Gale, Tien-Ying Hsiang, Lichen Jing, Michael R. Holbrook, Ian M. Kaplan, H. Jabran Zahid, Damon H. May, Jonathan M. Carlson, Lance Baldo, Thomas Manley, Harlan S. Robins, David M. Koelle
Summary: This study suggests that measuring T cell responses can provide reliable assessment of past SARS-CoV-2 infection and protective immunity. T cell responses showed significant correlations with neutralizing antibody titers and disease severity indicators. T cell testing demonstrated high sensitivity even after 6 months of infection, outperforming serology tests in identifying prior infection, especially in individuals with milder disease.
Article
Biology
Sean M. Hughes, Claire N. Levy, Fernanda L. Calienes, Katie A. Martinez, Stacy Selke, Kenneth Tapia, Bhavna H. Chohan, Lynda Oluoch, Catherine Kiptinness, Anna Wald, Mimi Ghosh, Liselotte Hardy, Kenneth Ngure, Nelly R. Mugo, Florian Hladik, Alison C. Roxby
Summary: This study investigated changes in immune mediators in the cervicovaginal tract of Kenyan AGYW before and after first sexual intercourse, and combined the results with two other studies through meta-analysis. The study found a significant increase in concentrations of immune mediators after first sex, with cumulative effects over time. These findings were consistent across three studies conducted on different continents.
Article
Virology
Linhui Hao, Tien-Ying Hsiang, Ronit R. Dalmat, Renee Ireton, Jennifer F. Morton, Caleb Stokes, Jason Netland, Malika Hale, Chris Thouvenel, Anna Wald, Nicholas M. Franko, Kristen Huden, Helen Y. Chu, Alex Sigal, Alex L. Greninger, Sasha Tilles, Lynn K. Barrett, Wesley C. Van Voorhis, Jennifer Munt, Trevor Scobey, Ralph S. Baric, David J. Rawlings, Marion Pepper, Paul K. Drain, Michael Gale
Summary: New variants of SARS-CoV-2 continue to emerge and evade immunity. Convalescence from the ancestral virus provides limited protection against variants. Vaccination enhances immunity against viral variants, but the protection is weaker against Omicron BA.1, and a three-dose vaccine regimen provides significantly better protection against it compared to a two-dose.
Editorial Material
Ethics
Tara M. Babu, Anna Wald
AMERICAN JOURNAL OF BIOETHICS
(2023)